BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 37341495)

  • 1. Efficacy of oseltamivir treatment in influenza virus-infected obese mice.
    Honce R; Jones J; Meliopoulos VA; Livingston B; Sharp B; Estrada LD; Wang L; Caulfield W; Freeman B; Govorkova E; Schultz-Cherry S
    mBio; 2023 Aug; 14(4):e0088723. PubMed ID: 37341495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of aloin on viral neuraminidase and hemagglutinin-specific T cell immunity in acute influenza.
    Huang CT; Hung CY; Hseih YC; Chang CS; Velu AB; He YC; Huang YL; Chen TA; Chen TC; Lin CY; Lin YC; Shih SR; Dutta A
    Phytomedicine; 2019 Nov; 64():152904. PubMed ID: 31454654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuraminidase inhibitor resistance after oseltamivir treatment of acute influenza A and B in children.
    Stephenson I; Democratis J; Lackenby A; McNally T; Smith J; Pareek M; Ellis J; Bermingham A; Nicholson K; Zambon M
    Clin Infect Dis; 2009 Feb; 48(4):389-96. PubMed ID: 19133796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oseltamivir-resistant novel influenza A (H1N1) virus infection in two immunosuppressed patients - Seattle, Washington, 2009.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2009 Aug; 58(32):893-6. PubMed ID: 19696719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of the rapid emergence of the H275Y mutation associated with oseltamivir resistance in severe pandemic influenza virus A/H1N1 09 infections.
    Wang B; Dwyer DE; Blyth CC; Soedjono M; Shi H; Kesson A; Ratnamohan M; McPhie K; Cunningham AL; Saksena NK
    Antiviral Res; 2010 Jul; 87(1):16-21. PubMed ID: 20385168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting Permissive Mutations That Improve the Fitness of A(H1N1)pdm09 Viruses Bearing the H275Y Neuraminidase Substitution.
    Farrukee R; Gunalan V; Maurer-Stroh S; Reading PC; Hurt AC
    J Virol; 2022 Aug; 96(15):e0091822. PubMed ID: 35867563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Host-targeted nitazoxanide has a high barrier to resistance but does not reduce the emergence or proliferation of oseltamivir-resistant influenza viruses in vitro or in vivo when used in combination with oseltamivir.
    Tilmanis D; Koszalka P; Barr IG; Rossignol JF; Mifsud E; Hurt AC
    Antiviral Res; 2020 Aug; 180():104851. PubMed ID: 32544408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Virus load kinetics and resistance development during oseltamivir treatment in infants and children infected with Influenza A(H1N1) 2009 and Influenza B viruses.
    Rath B; von Kleist M; Tief F; Karsch K; Tuerk E; Muehlhans S; Louis F; Skopnik H; Schweiger B; Duwe S
    Pediatr Infect Dis J; 2012 Sep; 31(9):899-905. PubMed ID: 22581220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical effectiveness of oseltamivir and zanamivir for treatment of influenza A virus subtype H1N1 with the H274Y mutation: a Japanese, multicenter study of the 2007-2008 and 2008-2009 influenza seasons.
    Kawai N; Ikematsu H; Hirotsu N; Maeda T; Kawashima T; Tanaka O; Yamauchi S; Kawamura K; Matsuura S; Nishimura M; Iwaki N; Kashiwagi S
    Clin Infect Dis; 2009 Dec; 49(12):1828-35. PubMed ID: 19911968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A two-year survey of the oseltamivir-resistant influenza A(H1N1) virus in Yamagata, Japan and the clinical effectiveness of oseltamivir and zanamivir.
    Matsuzaki Y; Mizuta K; Aoki Y; Suto A; Abiko C; Sanjoh K; Sugawara K; Takashita E; Itagaki T; Katsushima Y; Ujike M; Obuchi M; Odagiri T; Tashiro M
    Virol J; 2010 Mar; 7():53. PubMed ID: 20202225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of oseltamivir-resistant influenza A(H1N1)pdm09 viruses in Taiwan in 2009-2011.
    Yang JR; Huang YP; Chang FY; Hsu LC; Huang HY; Pan YT; Lin YC; Wu HS; Liu MT
    J Med Virol; 2013 Mar; 85(3):379-87. PubMed ID: 23280715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of antiviral agents for the management of severe influenza.
    Smith JR; Ariano RE; Toovey S
    Crit Care Med; 2010 Apr; 38(4 Suppl):e43-51. PubMed ID: 19935416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lactobacillus delbrueckii ssp. bulgaricus OLL1073R-1 feeding enhances humoral immune responses, which are suppressed by the antiviral neuraminidase inhibitor oseltamivir in influenza A virus-infected mice.
    Takahashi E; Sawabuchi T; Kimoto T; Sakai S; Kido H
    J Dairy Sci; 2019 Nov; 102(11):9559-9569. PubMed ID: 31495632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Five years of monitoring for the emergence of oseltamivir resistance in patients with influenza A infections in the Influenza Resistance Information Study.
    Lina B; Boucher C; Osterhaus A; Monto AS; Schutten M; Whitley RJ; Nguyen-Van-Tam JS
    Influenza Other Respir Viruses; 2018 Mar; 12(2):267-278. PubMed ID: 29265727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selection and viral load kinetics of an oseltamivir-resistant pandemic influenza A (H1N1) virus in an immunocompromised patient during treatment with neuraminidase inhibitors.
    Antón A; López-Iglesias AA; Tórtola T; Ruiz-Camps I; Abrisqueta P; Llopart L; Marcos MÁ; Martínez MJ; Tudó G; Bosch F; Pahissa A; de Anta MT; Pumarola T
    Diagn Microbiol Infect Dis; 2010 Nov; 68(3):214-9. PubMed ID: 20955912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo.
    Ives JA; Carr JA; Mendel DB; Tai CY; Lambkin R; Kelly L; Oxford JS; Hayden FG; Roberts NA
    Antiviral Res; 2002 Aug; 55(2):307-17. PubMed ID: 12103431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging oseltamivir resistance in seasonal and pandemic influenza A/H1N1.
    Renaud C; Kuypers J; Englund JA
    J Clin Virol; 2011 Oct; 52(2):70-8. PubMed ID: 21684202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emergence of H274Y oseltamivir-resistant A(H1N1) influenza viruses in Japan during the 2008-2009 season.
    Baranovich T; Saito R; Suzuki Y; Zaraket H; Dapat C; Caperig-Dapat I; Oguma T; Shabana II; Saito T; Suzuki H;
    J Clin Virol; 2010 Jan; 47(1):23-8. PubMed ID: 19962344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiviral resistance due to deletion in the neuraminidase gene and defective interfering-like viral polymerase basic 2 RNA of influenza A virus subtype H3N2.
    Trebbien R; Christiansen CB; Fischer TK
    J Clin Virol; 2018 May; 102():1-6. PubMed ID: 29448067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced effectiveness of oseltamivir in children infected with oseltamivir-resistant influenza A (H1N1) viruses with His275Tyr mutation.
    Saito R; Sato I; Suzuki Y; Baranovich T; Matsuda R; Ishitani N; Dapat C; Dapat IC; Zaraket H; Oguma T; Suzuki H
    Pediatr Infect Dis J; 2010 Oct; 29(10):898-904. PubMed ID: 20442686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.